Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors.

被引：2
|
作者：
Santana, V. M. [1 ]
Baker, S. D. [1 ]
McCarville, B. [1 ]
Stewart, C. F. [1 ]
Wu, J. [1 ]
Billups, C. [1 ]
Spunt, S. L. [1 ]
Furman, W. L. [1 ]
McGregor, L. M. [1 ]
Hu, S. [1 ]
Panetta, J. C. [1 ]
Reddick, W. E. [1 ]
Davidoff, A. [1 ]
Leung, W. H. [1 ]
Navid, F. [1 ]
机构：
[1] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.9500
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9500
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I expansion cohort to evaluate bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumors.
    Federico, Sara Michele
    McCarville, Mary B.
    Stewart, Clinton F.
    Mao, Shenghua
    Wu, Jianrong
    Davidoff, Andrew M.
    Furman, Wayne Lee
    Santana, Victor M.
    Pappo, Alberto S.
    Navid, Fariba
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors
    Navid, Fariba
    Baker, Sharyn D.
    McCarville, M. Beth
    Stewart, Clinton F.
    Billups, Catherine A.
    Wu, Jianrong
    Davidoff, Andrew M.
    Spunt, Sheri L.
    Furman, Wayne L.
    McGregor, Lisa M.
    Hu, Shuiying
    Panetta, John C.
    Turner, David
    Fofana, Demba
    Reddick, Wilburn E.
    Leung, Wing
    Santana, Victor M.
    CLINICAL CANCER RESEARCH, 2013, 19 (01) : 236 - 246
  • [3] Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors (vol 19, pg 236, 2013)
    Navid, Fariba
    CLINICAL CANCER RESEARCH, 2013, 19 (07) : 1914 - 1914
  • [4] Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours
    Federico, Sara M.
    Caldwell, Kenneth J.
    McCarville, Mary B.
    Daryani, Vinay M.
    Stewart, Clinton F.
    Mao, Shenghua
    Wu, Jianrong
    Davidoff, Andrew M.
    Santana, Victor M.
    Furman, Wayne L.
    Pappo, Alberto S.
    Navid, Fariba
    EUROPEAN JOURNAL OF CANCER, 2020, 132 : 35 - 42
  • [5] Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.
    Federico, Sara Michele
    Stewart, Elizabeth
    Coleman, Jamie L.
    Bishop, Michael William
    Santana, Victor M.
    Lam, Catherine
    Hawkins, Dana
    Wu, Jianrong
    Mao, Shenghua
    Goshorn, David Ross
    Papp, Alberto S.
    Dyer, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors.
    Chiorean, E. G.
    Matei, D.
    Younger, A.
    Funke, J. M.
    Waddell, M. J.
    Jones, D. R.
    Hahn, N. M.
    Perkins, S. M.
    Sandrasegaran, K.
    Sweeney, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] A phase II study of pazopanib in children, adolescents, and young adults with refractory solid tumors.
    Lee, Alice
    Bender, Julia Glade
    Weigel, Brenda
    Fox, Elizabeth
    Huff, Anne C.
    Tada, Hiroomi
    Blaney, Susan M.
    Langmuir, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors.
    Westin, Shannon Neville
    Smart, Melody L.
    Pal, Navdeep
    Urbauer, Diana L.
    Janku, Filip
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Naing, Aung
    Tsimberidou, Apostolia Maria
    Fu, Siqing
    Falchook, Gerald Steven
    Hong, David S.
    Zinner, Ralph
    Subbiah, Vivek
    Culotta, Kirk Salvatore
    Lu, Karen H.
    Coleman, Robert L.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors.
    Tsai, Hui-Jen
    Chiang, Nai-Jung
    Shiah, Her-Shyong
    Chang, Kwang-Yu
    Su, Wu-Chou
    Chang, Jang-Yang
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] Phase I study of pemetrexed and sorafenib in advanced solid tumors.
    Poklepovic, Andrew Stewart
    Shafer, Danielle A.
    Roberts, John D.
    Geyer, Charles E.
    Dent, Paul
    Moran, Richard
    Tombes, Mary Beth
    Shrader, Ellen
    Strickler, Kathryn
    Wan, Wen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345